Keytruda Cancer Treatment and Samsung Bioepis' SB27: Important Considerations
Samsung Bioepis' SB27: First-Mover Strategy in the Keytruda Biosimilar Market
South Korea's Samsung Bioepis is currently advancing its regulatory submission for SB27, a biosimilar to Keytruda (pembrolizumab), making it the first company to file for approval in this market. With Keytruda's patent expiration approaching, Samsung Bioepis and Celltrion have emerged as key competitors in what could become a $4.4 trillion cancer drug market.
SB27 Development Status and Regulatory Timeline
Samsung Bioepis is currently conducting global Phase 3 clinical trials for SB27, aiming to complete patient recruitment by October 2025 and submit regulatory approval by the first half of 2026. This timeline aligns with the one-year anniversary of Keytruda's domestic reimbursement application in South Korea, signaling potential market shifts.
SB27 has already completed Phase 3 clinical trials demonstrating equivalence, and development is on track for completion this year. With Keytruda's patent expiration imminent, Samsung Bioepis is positioning itself to lead the biosimilar market.
Keytruda Biosimilar Market Competition Landscape
Keytruda (brand name: Keytruda) is a globally leading cancer treatment drug, and competition among biosimilars is intensifying. Samsung Bioepis and Celltrion are now major competitors in this space, with the market estimated at approximately 44 trillion won ($31 billion).
Samsung Bioepis has been sharing patient prescription data for its Humira biosimilar to strategically prepare for Keytruda biosimilar development. Research on expanding Keytruda's indications and combination therapies is ongoing, including preliminary results presented by EnkeiMax at ASCO regarding Keytruda in lung cancer combination therapy.
Market Outlook and Policy Influence
The Keytruda biosimilar market is projected to be worth around 44 trillion won, with Samsung Bioepis and Celltrion among the key players. As Keytruda's patent expiration approaches, companies developing biosimilars are focusing on strategic positioning.
South Korea's National Health Insurance Service has recently reconsidered some of the 13 indications for expanded reimbursement of Keytruda. This decision carries significant policy implications that must be considered alongside market dynamics.
Clinical Data and Market Shift Predictions
Through SB27, Samsung Bioepis aims to secure a competitive edge in the Keytruda biosimilar market. Commercialization preparations are underway following Phase 3 clinical trial completion, with attention focused on developments after April 5, 2024—the date global Phase 3 trials for SB27 began.
The Keytruda biosimilar market is expected to reach approximately 44 trillion won in size. Samsung Bioepis and Celltrion's competitive dynamics are anticipated to intensify as Keytruda's patent expiration nears, with potential market shifts expected around the one-year anniversary of Keytruda's domestic reimbursement application.

Key Facts Summary
South Korea's Samsung Bioepis is currently advancing its regulatory submission for SB27, a biosimilar to Keytruda (pembrolizumab), making it the first company to file for approval in this market. SB27 has completed global Phase 3 clinical trials and is preparing for commercialization, targeting regulatory approval by the first half of 2026.
Event Context and Market Shifts
With Keytruda's patent expiration approaching, Samsung Bioepis and Celltrion have emerged as key competitors in a market projected to reach approximately 44 trillion won. SB27 is currently in global Phase 3 trials, aiming for patient recruitment completion by October 2025 and regulatory submission by the first half of 2026.
South Korea's National Health Insurance Service has recently reconsidered some of the 13 indications for expanded reimbursement of Keytruda. This decision carries significant policy implications that must be considered alongside market dynamics.
Cause Analysis and Market Outlook
The Keytruda biosimilar market is projected to reach approximately 44 trillion won, with Samsung Bioepis and Celltrion's competition expected to intensify as Keytruda's patent expiration approaches. Companies positioning themselves for the biosimilar market are gaining attention.
Through SB27 development, Samsung Bioepis aims to increase market share, while research on expanding Keytruda's indications and combination therapies continues. EnkeiMax previously presented preliminary results at ASCO regarding Keytruda in lung cancer combination therapy.
Response and Safety Information
Samsung Bioepis' SB27 is a biosimilar to Keytruda, with stability confirmed through clinical data. Commercialization preparations are underway following Phase 3 trial completion, with developments after April 5, 2024—the global Phase 3 trial start date—being closely monitored.
The Keytruda biosimilar market is projected to reach approximately 44 trillion won, and Samsung Bioepis and Celltrion's competitive dynamics are expected to intensify. Policy factors related to the reconsideration of Keytruda reimbursement expansion applications must also be considered.
Information to Verify
Samsung Bioepis' SB27 aims to complete Phase 3 patient recruitment by October 2025 and submit regulatory approval by the first half of 2026, aligning with Keytruda's domestic reimbursement application one-year anniversary.
The Keytruda biosimilar market is estimated at around 44 trillion won, with Samsung Bioepis and Celltrion emerging as major competitors. Some of the 13 indications for expanded Keytruda reimbursement have recently been reconsidered by South Korea's National Health Insurance Service.
Frequently Asked Questions
When is Samsung Bioepis' SB27 regulatory submission scheduled?
South Korea's Samsung Bioepis aims to submit regulatory approval for SB27 by the first half of 2026.
What is the size of the Keytruda biosimilar market?
The Keytruda biosimilar market is projected to be approximately 44 trillion won (around $31 billion).
How does Samsung Bioepis and Celltrion's competition look in the Keytruda biosimilar market?
South Korea's Samsung Bioepis and Celltrion have emerged as key competitors in the Keytruda biosimilar market.
Frequently Asked Questions
Keytruda biosimilar development with Samsung Bioepis' SB27, along with the $44 trillion market outlook, is gaining attention. Samsung Bioepis aims to increase market share through SB27 development, while considering policy factors related to Keytruda reimbursement expansion reconsiderations.
As Keytruda's patent expiration approaches, companies developing biosimilars are positioning themselves strategically for market leadership. Samsung Bioepis' SB27 development is a key factor in anticipating market shifts as the industry moves toward the one-year anniversary of Keytruda's domestic reimbursement application.
Explore more articles on similar topics.
View Related ArticlesFAQ
When is Samsung Bioepis' SB27 regulatory submission scheduled?
South Korea's Samsung Bioepis aims to submit regulatory approval for SB27 by the first half of 2026.
What is the size of the Keytruda biosimilar market?
The Keytruda biosimilar market is projected to be approximately 44 trillion won (around $31 billion).
How does Samsung Bioepis and Celltrion's competition look in the Keytruda biosimilar market?
South Korea's Samsung Bioepis and Celltrion have emerged as key competitors in the Keytruda biosimilar market.
Korean Source
This article is an English localization of a Korean-language report from BlogScore. Original: 키트루다 암 치료에 삼성바이오에피스 사용 시 주의 사항